(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.
At constant exchange rates total revenues jumped 19% to reach approximately $12.17bn (consensus: $11.8bn).

Core earnings per share were ahead by 13% to $2.06 (consensus:...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE